An Osaka University-led research team has recently published findings that provide a ray of hope for the millions of Parkinson’s disease (PD) sufferers worldwide. Although more common in those aged over sixty, PD can strike at any age, with an estimated prevalence of 41 per 100,000 people in their forties. And while not fatal in and of itself, the progressive neurodegeneration that is characteristic of PD can often cause secondary effects that lead to death.
The exact cause of PD is still a mystery, but researchers believe that both genetics and the environment are likely to play a part. Importantly though, all PD patients show a loss of dopaminergic neurons in the brain and increased levels of a protein called ?-synuclein, which accumulates in Lewy bodies. Lewy bodies are a pathological feature of both familial and sporadic forms of the disease, as well as some types of dementia.
In the study published this month in Scientific Reports, the team led by researchers from Osaka University’s Graduate School of Medicine focused on ?-synuclein as a target for a novel PD treatment.
“Although there are drugs that treat the symptoms associated with PD, there is no fundamental treatment to control the onset and progression of the disease,” explains lead author Takuya Uehara. “Therefore, we looked at ways to prevent the expression of ?-synuclein and effectively eliminate the physiological cause of PD.”
To do this, the researchers designed short fragments of DNA that are mirror images of sections of the ?-synuclein gene product. The constructs were stabilized by the addition of amido-bridging. The resulting fragments, called amido-bridged nucleic acid-modified antisense oligonucleotides (ASOs), bind to their matching mRNA sequence, preventing it from being translated into protein. After screening 50 different ASOs, the researchers settled on a 15-nucleotide sequence that decreased ?-synuclein mRNA levels by 81%.
“When we tested the ASO in a mouse model of PD, we found that it was delivered to the brain without the need for chemical carriers,” says co-lead author Chi-Jing Choong. “Further testing showed that the ASO effectively decreased ?-synuclein production in the mice and significantly reduced the severity of disease symptoms within 27 days of administration.”
Explains senior author of the study Hideki Mochizuki, “Our results showed that gene therapy using ?-synuclein-targeting ASOs is a promising strategy for the control and prevention of PD. We expect that in the future, this method will be used to not only successfully treat PD, but also dementia caused by ?-synuclein accumulation.”
Learn more: Stopping Parkinson’s disease before it starts
The Latest on: Parkinson’s disease
via Google News
The Latest on: Parkinson’s disease
- Cells carrying Parkinson's mutation could lead to new model for studying diseaseon February 27, 2020 at 9:48 am
Parkinson's disease researchers have used gene-editing tools to introduce the disorder's most common genetic mutation into marmoset monkey stem cells and to successfully tamp down cellular ...
- Renishaw completes main part of Phase 1-2 clinical trial along with Herantis Pharma for treatment of Parkinson’s diseaseon February 27, 2020 at 7:38 am
Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device, has played a critical role in a joint Phase 1-2 clinical study with Herantis ...
- Innovative ways to battle Parkinson's diseaseon February 27, 2020 at 7:38 am
Peter Brust has won HZDR's (Helmholtz-Zentrum Dresden-Rossendorf) third Innovation Contest. The researchers succeeded in developing a new substance that could improve image-based differential ...
- Madison Area Y Offers Parkinson's Programming Five Days Per Weekon February 27, 2020 at 6:39 am
One of your neighbors posted in Health & Fitness. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
- The Michael J. Fox Foundation for Parkinson's Research Announces New Chairman of the Board, Biopharma Leader Skip Irvingon February 27, 2020 at 6:12 am
Fox Foundation for Parkinson's Research Announces New Chairman of the Board, Biopharma Leader Skip IrvingPR NewswireNEW YORK, Feb. 27, 2020 /PRNewswire/ -- The Michael J.
- EMT becomes voice of support for others living with Parkinson’s Diseaseon February 26, 2020 at 5:33 pm
EASTON, Pa. - Eric Aquino has dedicated his life to helping others, first through his work as an EMT and now behind the mic as a voice of support for others living with Parkinson’s Disease. When ...
- Ping pong holds promise for improving Parkinson’s symptomson February 26, 2020 at 4:21 pm
which is why a new study out of Japan's Fukuoka University is so intriguing. The researchers found that playing ping pong may lead to significant improvements in Parkinson’s symptoms. Ping pong!
- Playing ping pong could benefit patients with parkinson's diseaseon February 26, 2020 at 11:24 am
Study: after three months the patients showed significant improvements in speech, handwriting, getting dressed and walking.
- Pingpong "significantly improves" Parkinson's symptoms in pilot studyon February 25, 2020 at 10:53 pm
Researchers in Japan have turned their eye to its potential to treat symptoms of Parkinson's disease, with a six-month preliminary study pointing to significant improvements in the participant's ...
- Former Yorktown star Bruce Parkinson reflects on career, Purdue Athletic Hall of Fame inductionon February 25, 2020 at 1:24 pm
Bruce Parkinson didn't expect any of this. Last week, the former Yorktown hoops star became a member of Purdue's 2020 Hall of Fame class.
via Bing News